about
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemiaRecurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome.Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients.A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia.The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemiaA phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosisIL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemiaIn vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemiaOptimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing dataAllogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO eraRevealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia.Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.New targets for Ph+ leukaemia therapy.Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments.Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells.SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto AcuteUse of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response.Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule.Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia.Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia.Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainComplete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.A case report of acute myeloid leukemia and neurofibromatosis 1.A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients.
P50
Q27851487-89CB47F2-49A3-4A51-8C65-8BD37C1F5BF5Q28390558-FD730A39-9FA9-414A-BD00-03CB5C4FAD54Q33409349-8B761ECD-C7E8-4716-9E43-69FB099A648FQ33421005-4FC3EECD-3E9A-4BEE-9E34-9FD421C26D2EQ33431360-CB39A022-7AE7-4FD5-915C-CE99C1BB8D27Q33849578-31AD8976-865B-42EF-A59F-2E795C279D71Q34166538-CE84FA86-7DBD-426D-AB47-0CF8D03673ACQ34325815-A7253DFA-F311-4F03-A040-7B3E395AB001Q34358106-3F1C9DD7-2588-4DA7-8685-3BDF0F959B16Q34448958-92AF8401-1646-46DB-A9E0-D61AD36B9E43Q34750545-463BDEF0-A5A6-40DA-90ED-C53AC10084DEQ35853686-7E4B8AAC-DD91-4B9C-B4C1-7DB6AE8E517BQ36255484-92212B9C-A113-459F-8D6D-5F4EEFF3584AQ36276444-E246F1B7-A96F-428A-B66A-EA4008DB9CBEQ36366631-6AD9E51C-9541-49E1-8BAF-998069F994FCQ36544560-D44AE2CF-D7A7-4DF1-8433-20E25A4574C4Q37183513-734222B4-0582-47DA-A852-24303E2B36C5Q37362705-31149A52-9F07-437D-BD87-23E7D3F18C40Q37644029-B6A14A28-9B03-4E0C-AB99-458986B959D6Q38005040-6FB143F5-4796-4FA1-984D-BDFDD6667E4FQ38289019-8A1A74A9-4A3C-4A1B-84D6-D80DB2526EC9Q38374992-078EA75F-7CFD-475C-9126-F9F9F90061BEQ38698612-55F66904-AABD-4021-9637-097E5E827621Q38739574-45539C5A-E57B-4A91-A360-4F7375F38073Q38756843-137BE2D8-C9D1-4459-992B-FF65EA8E381BQ38793389-F03FF155-AAD2-4A77-9491-7DB613F701C8Q38797003-534DB52B-41A6-4DDD-B33D-B49C0D1B44FEQ39826912-C6B29069-3131-40E3-92D8-0F1714DD6F8FQ40177674-35335B04-2702-4086-8DCB-FC82DAE05F18Q40996735-3601EB52-E3C2-4309-9669-3EB9443A4B3CQ41264328-6881BA98-C965-4291-B692-C3D2FF902273Q41701253-B697DB0F-9E2F-4D77-9A16-70B7C21C24BBQ42132407-EADCA7E8-A7BD-4A8C-965F-49C82D504DBAQ42145852-1E37328E-3ACE-4154-BD6D-B87129283556Q42699939-DC8667E6-63D1-4865-A87D-38994B3471D0Q42811718-1D363E17-8A12-4EC5-BD12-C6DA76ACD421Q42958229-5947A72B-04CE-4475-A2FF-78B6406A390EQ43080898-C289ED83-3765-4FD5-A44A-F13CDC4CC95CQ43170125-ADCC8163-1C0A-4DCD-8576-1A5880FC68B6Q43275641-44033072-B66F-45FC-A222-1E0B8B19AD52
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cristina Papayannidis
@ast
Cristina Papayannidis
@en
Cristina Papayannidis
@es
Cristina Papayannidis
@nl
Cristina Papayannidis
@sl
type
label
Cristina Papayannidis
@ast
Cristina Papayannidis
@en
Cristina Papayannidis
@es
Cristina Papayannidis
@nl
Cristina Papayannidis
@sl
prefLabel
Cristina Papayannidis
@ast
Cristina Papayannidis
@en
Cristina Papayannidis
@es
Cristina Papayannidis
@nl
Cristina Papayannidis
@sl
P106
P21
P31
P496
0000-0001-8705-8333